SOPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SOPHiA GENETICS SA (SOPH) is not a strong buy at this moment for a beginner investor with a long-term strategy. While hedge funds are significantly increasing their holdings and analysts have raised the price target with a Buy rating, the technical indicators do not suggest a clear upward trend, and the financial performance, though improving, still shows negative net income and EPS. Additionally, there are no recent news catalysts or strong trading signals to support immediate action.
The MACD histogram is negative and contracting (-0.0326), indicating bearish momentum. RSI at 30.549 is neutral, and moving averages are converging, showing no clear trend. The stock is trading near a key support level (S1: 4.512), but there is no strong indication of a reversal or breakout.
Hedge funds have increased their holdings by 1033.12% in the last quarter. Analysts have raised the price target to $7 with a Buy rating.
No recent news or significant insider trading activity. The gross margin has slightly declined YoY, and the company is still operating at a net loss.
In Q3 2025, revenue increased by 22.77% YoY to $19.46M. Net income improved by 8.59% YoY but remains negative at -$20.02M. EPS improved by 7.14% YoY to -0.3. Gross margin dropped slightly to 66.32%, down 1.31% YoY.
Guggenheim raised the price target from $6 to $7 and maintained a Buy rating, reflecting optimism about the company's growth potential in the diagnostics and life sciences tools sector.
